Commodore Capital’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Commodore Capital’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-127,156	Closed	-$13.6M	–	34
2023 Q1	$13.6M	Hold	127,156	–	–	2.08%	19
2022 Q4	$14M	Buy	+127,156	New	+$8.25M	2.11%	17

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Commodore Capital's RXDX Position: Q2 2023 in Review

Commodore Capital sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 127,156 shares — an estimated $13.6M sold.

Commodore Capital first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $14M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Commodore Capital reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Commodore Capital sold 127,156 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.6M.
Commodore Capital first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Commodore Capital's Prometheus Biosciences, Inc. Common Stock position peaked at $14M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.